Source comparison
Tesamorelin Before and After Real Results: Clinical vs Anecdotal Comparisons
Visceral Fat Reduction 15.2% mean reduction vs 4.9% placebo (CT-measured) '30–40% fat loss' Clinical data is mechanism-consistent; anecdotal claims conflate visceral + subcutaneous fat or misattribute diet-driven results Scale Weight Change −2.2kg mean vs −0.8
This comparison does not assign a generated winner or score.
- Visceral Fat Reduction
- 15.2% mean reduction vs 4.9% placebo (CT-measured)
- '30–40% fat loss'
- Clinical data is mechanism-consistent; anecdotal claims conflate visceral + subcutaneous fat or misattribute diet-driven results
- Scale Weight Change
- −2.2kg mean vs −0.8kg placebo
- '10–15kg weight loss'
- Tesamorelin is not a weight-loss compound. Dramatic scale drops suggest caloric deficit, not peptide effect
- Waist Circumference
- −4.2cm mean reduction at umbilicus
- '6–10cm waist reduction'
- 4–5cm is realistic at six months; larger reductions likely include dietary intervention
- Timeline to Visible Change
- 12–16 weeks for externally noticeable waist reduction
- 'Results in 4–6 weeks'
- Pituitary-mediated GH release creates inherent lag; claims of rapid visual changes don't align with GHRH pharmacokinetics
- Lean Mass Preservation
- No significant lean mass loss vs baseline
- 'Builds muscle while burning fat'
- Tesamorelin preserves lean mass during fat loss but doesn't build muscle without resistance training stimulus
- Metabolic Markers
- HbA1c reduction 0.3–0.5%, triglyceride reduction 12–18%
- Not typically mentioned in anecdotal claims
- The metabolic benefit is the clinical justification. Cosmetic changes are secondary